🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

INSYS Therapeutics presents data from safety study of CBD oral solution in refractory pediatric epilepsy

Published 12/04/2018, 07:33 AM
© Reuters.  INSYS Therapeutics presents data from safety study of CBD oral solution in refractory pediatric epilepsy
MO
-
INSYQ
-
  • INSYS Therapeutics' (NASDAQ:INSY) pharmaceutical-grade cannabidiol (CBD) oral solution was generally well-tolerated, even at high doses, as an investigational treatment for refractory pediatric epilepsy. The data was presented at the American Epilepsy Society 2018.
  • The presentation reported safety data from 52 patients. The mean modal dose was 24.42 mg/kg/day; and the mean total duration of study drug was 311.1 days (with a maximum exposure of 384 days).
  • Safety assessments included treatment-emergent adverse events (TEAEs), electrocardiograms, physical and neurologic exams and lab tests.
  • 90.4% patients experienced one or more TEAEs during the study; and 46.2% had TEAEs that were possibly or probably related to the study drug, most being mild or moderate in intensity.
  • Now read: Cronos Group confirms talks with Altria (NYSE:MO); shares up 14% premarket


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.